New drug combo aims to shrink Hard-to-Treat tumors
NCT ID NCT06480552
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This early-phase trial tests a new drug, TEV-56278, alone or with pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 240 adults with certain cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Teva Investigational Site 11282
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Teva Investigational Site 12014
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Teva Investigational Site 12015
RECRUITINGDetroit, Michigan, 48201, United States
-
Teva Investigational Site 12016
RECRUITINGChicago, Illinois, 60611, United States
-
Teva Investigational Site 12017
RECRUITINGLos Angeles, California, 90025, United States
-
Teva Investigational Site 12018
RECRUITINGFairfax, Virginia, 22031, United States
-
Teva Investigational Site 12019
RECRUITINGNashville, Tennessee, 37203, United States
-
Teva Investigational Site 12021
COMPLETEDLake Mary, Florida, 32746, United States
-
Teva Investigational Site 12023
RECRUITINGCincinnati, Ohio, 45219, United States
-
Teva Investigational Site 12025
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Teva Investigational Site 12058
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.